179 related articles for article (PubMed ID: 26834627)
41. Effects of intrahippocampal colchicine administration on the levels and localization of microtubule-associated proteins, tau and MAP2.
Geddes JW; Bondada V; Keller JN
Brain Res; 1994 Jan; 633(1-2):1-8. PubMed ID: 7511033
[TBL] [Abstract][Full Text] [Related]
42. The monoclonal antibody Alz-50, used to reveal cytoskeletal changes in Alzheimer's disease, also reacts with a large subpopulation of somatostatin neurons in the normal human hypothalamus and adjoining areas.
van de Nes JA; Sluiter AA; Pool CW; Kamphorst W; Ravid R; Swaab DF
Brain Res; 1994 Aug; 655(1-2):97-109. PubMed ID: 7812796
[TBL] [Abstract][Full Text] [Related]
43. The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset?
Grinberg LT; Rüb U; Ferretti RE; Nitrini R; Farfel JM; Polichiso L; Gierga K; Jacob-Filho W; Heinsen H;
Neuropathol Appl Neurobiol; 2009 Aug; 35(4):406-16. PubMed ID: 19508444
[TBL] [Abstract][Full Text] [Related]
44. Aluminum modifies the properties of Alzheimer's disease PHF tau proteins in vivo and in vitro.
Shin RW; Lee VM; Trojanowski JQ
J Neurosci; 1994 Nov; 14(11 Pt 2):7221-33. PubMed ID: 7525898
[TBL] [Abstract][Full Text] [Related]
45. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.
Kontsekova E; Zilka N; Kovacech B; Novak P; Novak M
Alzheimers Res Ther; 2014; 6(4):44. PubMed ID: 25478017
[TBL] [Abstract][Full Text] [Related]
46. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration.
Leroy K; Yilmaz Z; Brion JP
Neuropathol Appl Neurobiol; 2007 Feb; 33(1):43-55. PubMed ID: 17239007
[TBL] [Abstract][Full Text] [Related]
47. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau.
Jicha GA; Bowser R; Kazam IG; Davies P
J Neurosci Res; 1997 Apr; 48(2):128-32. PubMed ID: 9130141
[TBL] [Abstract][Full Text] [Related]
48. Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice.
Dewachter I; van Dorpe J; Spittaels K; Tesseur I; Van Den Haute C; Moechars D; Van Leuven F
Exp Gerontol; 2000 Sep; 35(6-7):831-41. PubMed ID: 11053674
[TBL] [Abstract][Full Text] [Related]
49. Phosphorylation events mediated by protein kinase C alpha and epsilon participate in regulation of tau steady-state levels and generation of certain "Alzheimer-like" phospho-epitopes.
Boyce JJ; Shea TB
Int J Dev Neurosci; 1997 Jun; 15(3):295-307. PubMed ID: 9253654
[TBL] [Abstract][Full Text] [Related]
50. Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer's disease mutants of APP and presenilin-1.
Boutajangout A; Authelet M; Blanchard V; Touchet N; Tremp G; Pradier L; Brion JP
Neurobiol Dis; 2004 Feb; 15(1):47-60. PubMed ID: 14751770
[TBL] [Abstract][Full Text] [Related]
51. Neurofibrillary tangles in progressive supranuclear palsy contain the same tau epitopes identified in Alzheimer's disease PHFtau.
Schmidt ML; Huang R; Martin JA; Henley J; Mawal-Dewan M; Hurtig HI; Lee VM; Trojanowski JQ
J Neuropathol Exp Neurol; 1996 May; 55(5):534-9. PubMed ID: 8627344
[TBL] [Abstract][Full Text] [Related]
52. [Alzheimer's disease: lesions and their progression].
Duyckaerts C; Colle MA; Delatour B; Hauw JJ
Rev Neurol (Paris); 1999; 155 Suppl 4():S17-27. PubMed ID: 10637934
[TBL] [Abstract][Full Text] [Related]
53. Early phosphorylation of tau in Alzheimer's disease occurs at Ser-202 and is preferentially located within neurites.
Su JH; Cummings BJ; Cotman CW
Neuroreport; 1994 Nov; 5(17):2358-62. PubMed ID: 7533559
[TBL] [Abstract][Full Text] [Related]
54. Alz-50 immunoreactivity in the hypothalamus of the normal and Alzheimer human and the rat.
Byne W; Mattiace L; Kress Y; Davies P
J Comp Neurol; 1991 Apr; 306(4):602-12. PubMed ID: 2071697
[TBL] [Abstract][Full Text] [Related]
55. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
Wang JZ; Grundke-Iqbal I; Iqbal K
Eur J Neurosci; 2007 Jan; 25(1):59-68. PubMed ID: 17241267
[TBL] [Abstract][Full Text] [Related]
56. A double-labeling immunohistochemical study of tau exon 10 in Alzheimer's disease, progressive supranuclear palsy and Pick's disease.
Ishizawa K; Ksiezak-Reding H; Davies P; Delacourte A; Tiseo P; Yen SH; Dickson DW
Acta Neuropathol; 2000 Sep; 100(3):235-44. PubMed ID: 10965792
[TBL] [Abstract][Full Text] [Related]
57. Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein.
Cras P; Kawai M; Lowery D; Gonzalez-DeWhitt P; Greenberg B; Perry G
Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7552-6. PubMed ID: 1652752
[TBL] [Abstract][Full Text] [Related]
58. Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer's disease.
Kovacech B; Novak M
Curr Alzheimer Res; 2010 Dec; 7(8):708-16. PubMed ID: 20678071
[TBL] [Abstract][Full Text] [Related]
59. Pick's disease: hyperphosphorylated tau protein segregates to the somatoaxonal compartment.
Probst A; Tolnay M; Langui D; Goedert M; Spillantini MG
Acta Neuropathol; 1996 Dec; 92(6):588-96. PubMed ID: 8960316
[TBL] [Abstract][Full Text] [Related]
60. Abnormal Expression and Distribution of MMP2 at Initial Stages of Alzheimer's Disease-Related Pathology.
Terni B; Ferrer I
J Alzheimers Dis; 2015; 46(2):461-9. PubMed ID: 26402409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
